ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Last trade$3.50
Day change+$0.30 (+9.37%)
Day range$3.12 – $4.03
Volume74,995
Market cap$40M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$39.86M
Price / earnings
—
Price / book
0.31×
Price / sales
—
EV / sales
—
EV / EBITDA
0.91×
Profitability
Earnings per share
-$3.48
Return on assets
-30.39%
Return on equity
-33.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.17×
Quick ratio
16.17×
Cash ratio
10.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$6.04M
$5.12M
$6.12M
$5.23M
$11.04M
Research and development
$11.27M
$6.67M
$5.96M
$3.27M
$15.16M
Total operating expenses
$17.31M
$11.78M
$12.08M
$8.5M
$26.19M
Operating income
-$17.31M
-$11.78M
-$12.08M
-$8.5M
-$26.19M
Interest expense
$1.19M
$1.25M
$1.13M
$0
$1.06M
Income before taxes
-$15.6M
-$10.16M
-$10.61M
-$7.18M
-$24.85M
Income taxes
$20K
$16K
$10K
-$276K
-$74K
Net income
-$15.62M
-$10.18M
-$10.62M
-$6.91M
-$24.78M
Net income attributable to common shareholders
-$15.62M
-$10.18M
-$10.62M
-$6.91M
-$25.63M
EBITDA
-$17.31M
-$11.78M
-$12.08M
-$8.11M
-$26.19M
Basic earnings per share
-$0.91
-$0.63
-$0.95
-$1.18
-$2.91
Diluted earnings per share
-$0.91
-$0.63
-$0.95
-$1.18
-$2.91
Recent news
Company coverage with links to the original publishers.
Research highlights emerging OX40/OX40L targeted therapies showing promise in treating inflammatory conditions like asthma and atopic dermatitis, with multiple pharmaceutical companies advancing clinical trials and developing innovative therapeutic approaches.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.